Business
IMC Presentation Statement
SkinBioTherapeutics plc will present to shareholders today, June 29, 2026, at 09:00 BST on the Investor Meet Company platform, covering recent post-period events, findings from the FRP Advisory report, and HY26 results, alongside post-period trading and outlook. The company will confirm that its FY26 results will be prepared on a going concern basis. Disclaimer*
About this update from Skinbiotherapeutics Plc
SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Company" or the "Group") IMC Presentation Statement 29 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, will be presenting to shareholders at 09.00 BST today, Monday 29 June 2026 on the Investor Meet Company platform (see details below). The presentation will be led by Alyson Levett, Acting Chair and Rachel Parsonage, Interim CEO. The presentation will be brief and cover recent post period events, the investigation and the disclosable information from the FRP Advisory report, before running through the recent HY26 results, post period trading and outlook. The Company will also be stating that the FY26 results will be prepared on a going concern basis. Presentation details The presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics via the link HERE. Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited. -Ends- For more information please contact: SkinBioTherapeutics plc Alyson Levett, Acting Chair Rachel Parsonage, Interim CEO [email protected] Singer Capital Markets (Nominated Adviser & Broker) Alex Bond Sara Hale Patrick Weaver +44 (0) 020 7496 3000 Vigo Consulting Melanie Toyne-Sewell, Rozi Morris +44 (0) 20 7390 0230 [email protected] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester. The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain. SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufa...
View stock analysis, news, and events for Skinbiotherapeutics Plc